Vikas Sinha - 20 Jan 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
ALVR
Transactions as of
20 Jan 2022
Transactions value $
-$56,454
Form type
4
Filing time
24 Jan 2022, 15:15:11 UTC
Previous filing
04 Apr 2022
Next filing
22 Apr 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Sale -$56,454 -6,450 -0.75% $8.75 858,957 20 Jan 2022 Direct F1, F2
holding ALVR Common Stock 13,420,970 20 Jan 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Officer Title: President & Chief Financial Officer